InvestorsHub Logo
Followers 69
Posts 12025
Boards Moderated 0
Alias Born 08/01/2009

Re: None

Friday, 02/18/2011 8:33:49 AM

Friday, February 18, 2011 8:33:49 AM

Post# of 485
CHBT filed 5 new patents as a direct result of its increased R&D efforts. Now they have a 40-man strong R&D team devoted to bump this company up to top R&D standards and rapidly increase its market share in probiotics acc. to most recent 10Q:

Research and development (R&D) expenses increased to $1.9 million from $0.8 million in the third quarter of fiscal year 2010. R&D expenses as a percentage of revenue were 5.8%, as compared to 3.3% for the third quarter of fiscal year 2010. The Company established a strong research and development team supported by over 10 PhDs and 30 masters' degree holders. Dr. Chungchang Tao, formerly with Coca-Cola's Global Innovation & Technology Center in Shanghai, joined the Company as its R&D Director. Dr. Tao holds a PhD in Biological & Agricultural Engineering from the University of Idaho. In addition, the number of probiotics strains in the Company's proprietary strain library has now increased to over 1,000. The Company will continue to invest in its core technology of bacteria cultures and preservation, while expanding its product line and applications to address specific health problems.

http://finance.yahoo.com/news/ChinaBiotics-Files-for-5-New-prnews-1988181149.html?x=0&.v=1